· PC
· PK
· PD
Structure/class |
· Synthetic opioid · Phenylpiperidine derivative · Ester linkage |
Presentation |
· Lyophillised white powder remifentanil HCl · Reconstituted with saline · Glycine additive (hence not for intrathecal use) |
Administration |
· Bolus 0.5-1mcg/kg for induction or intubation · Infusion 0.025-0.2mcg/kg/min · Infusion TCI Ce 2-6ng/mL (e.g. Minto model) |
Time course |
· Onset: <1 min · Peak: 1.8 mins · Duration: 3-5mins (rapid metabolism) |
Absorption |
· Oral bioav low |
Distribution |
· Rapid effect site equilibration, t1/2ke0 1.5 mins o Moderate lipid solubility 20x morphine o Weak base pKa 7.1, 68% unionised at pH 7.4, plasma protein binding 70% · Very small VDSS 0.3L/kg |
Metabolism |
· Hydrolyis by non-specific esterases in plasma and muscle · i.e. multicompartment and organ-independent · Fast Cl 40mL/kg/min · ↑Cl + ↓VDSS = short t1/2β 10 mins · Carboxylic acid metabolite 1/1000 as active |
Excretion |
· Metabolites -> urine |
Mechanism |
· Pure μ opioid receptor agonist |
Analgesic effect |
· Supraspinal (e.g. PAG): inhibit OFF cell -> disinhibit ON cell -> ↑descending modulation via noradrenaline and serotonin -> pre-synaptic inhibition at dorsal horn · Spinal (dorsal horn): pre-synaptic inhibition of nociceptors · Risk of severe pain when infusion ceased · Risk of hyperalgaesia and tolerance if prolonged, high dose infusion |
Other CNS effects |
· Sedation (M receptors in the medulla) +/- unconsciousness · Miosis: (M receptor in CNIII EW nucleus) · Euphoria, dysphoria, hallucination |
CVS effects |
· ↓SNS output from medulla, ↑PSNS output via CNX · ↓HR, +/- arrest if bolus (Rx atropine) · ↓SVR, ↓mAP |
Respiratory effects |
· Respiratory centre depression: o Decreased RR more than VT o Apnoea if bolused · Airway reflex depression, anti-tussive · Chest wall rigidity if bolused o M receptor on GABA-ergic neurons in basal ganglia o May herald unconsciousness o Rx: paralysis |
Other |
· Most other opioid side effects uncommon due to o Used primarily under GA o Rapid offset · ↓GIT motility · Urinary retention · ↓Immune function · ↓Hypothalamic/pituitary function -> hypogonadism, osteoporosis |
Indications/use |
· TIVA with propofol · Synergistic adjunct to propofol or volatile anaesthetic o Reduces nociceptive activation of reticular activating system o Hence ↓MAC, ↓Cp50 propofol · ETT tolerance: o Facilitate intubation without paralysis (e.g. neuromuscular disorder) o Cough free emergence (if high risk of secondary bleeding) · Reduce bleeding in sinus surgery · Facilitate rapid emergence up for neurological assessment (e.g. with desflurane) · PCA for labour analgesia (rapid onset and offset, minimal effect on foetus) |
Feedback welcome at ketaminenightmares@gmail.com